GBS (GBS) Stock Price, News & Analysis

Company Overview

GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Key Stats

• Today's Range: $1.75 to $1.85
• 50-Day Range: $1.15 to $1.98
• 52-Week Range: $0.36 to $2.89
• Volume: 508,618 shs
• Average Volume: 955,325 shs
• Market Capitalization: $26.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GBS Stock Analysis - Frequently Asked Questions

How have GBS shares performed this year?

GBS's stock was trading at $1.40 on January 1st, 2025. Since then, GBS stock has increased by 27.1% and is now trading at $1.78.

How were GBS's earnings last quarter?

GBS Inc. (NYSE:GBS) posted its quarterly earnings results on Wednesday, August, 31st. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.04.

How do I buy shares of GBS?

Shares of GBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of GBS own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GBS investors own include Athenex (ATNX), Biora Therapeutics (BIOR), Citius Pharmaceuticals (CTXR), KLX Energy Services (KLXE), BSQUARE (BSQR), Communications Systems (JCS) and Meta Platforms (META).

Company Calendar

• Last Earnings: 8/31/2022
• Today: 7/08/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: N/A
• Current Symbol: NYSE:GBS
• CIK: 1725430
• Web: www.gbs.inc
• Phone: 646 828 8258
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.31 million
• Net Margins: N/A
• Pretax Margin: -1,907.09%
• Return on Equity: -85.64%
• Return on Assets: -54.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.33
• Quick Ratio: 2.33

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.44 per share
• Price / Book: 4.05

Miscellaneous

• Outstanding Shares: 14,890,000
• Free Float: 14,850,000
• Market Cap: $26.50 million
• Optionable: Not Optionable
• Beta: 1.32